194 related articles for article (PubMed ID: 11597382)
21. Determination of imbalance between MMP-2 and TIMP-2 in human neuroblastoma by reverse-transcription polymerase chain reaction and its correlation with tumor progression.
Ara T; Kusafuka T; Inoue M; Kuroda S; Fukuzawa M; Okada A
J Pediatr Surg; 2000 Mar; 35(3):432-7. PubMed ID: 10726683
[TBL] [Abstract][Full Text] [Related]
22. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.
Bhuvarahamurthy V; Kristiansen GO; Johannsen M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2006 May; 15(5):1379-84. PubMed ID: 16596214
[TBL] [Abstract][Full Text] [Related]
23. Malignant effusions are sources of fibronectin and other promigratory and proinvasive components.
Kohn EC; Travers LA; Kassis J; Broome U; Klominek J
Diagn Cytopathol; 2005 Nov; 33(5):300-8. PubMed ID: 16240400
[TBL] [Abstract][Full Text] [Related]
24. Caveolin-1 expression in ovarian carcinoma is MDR1 independent.
Davidson B; Goldberg I; Givant-Horwitz V; Nesland JM; Berner A; Bryne M; Risberg B; Kopolovic J; Kristensen GB; Tropé CG; van de Putte G; Reich R
Am J Clin Pathol; 2002 Feb; 117(2):225-34. PubMed ID: 11863219
[TBL] [Abstract][Full Text] [Related]
25. Gonadotropin and steroid regulation of matrix metalloproteinases and their endogenous tissue inhibitors in the developed corpus luteum of the rhesus monkey during the menstrual cycle.
Young KA; Stouffer RL
Biol Reprod; 2004 Jan; 70(1):244-52. PubMed ID: 13679308
[TBL] [Abstract][Full Text] [Related]
26. The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma.
Davidson B; Goldberg I; Gotlieb WH; Kopolovic J; Ben-Baruch G; Nesland JM; Reich R
Mol Cell Endocrinol; 2002 Feb; 187(1-2):39-45. PubMed ID: 11988310
[TBL] [Abstract][Full Text] [Related]
27. Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors.
Määttä M; Santala M; Soini Y; Talvensaari-Mattila A; Turpeenniemi-Hujanen T
Tumour Biol; 2004; 25(4):188-92. PubMed ID: 15557756
[TBL] [Abstract][Full Text] [Related]
28. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
[TBL] [Abstract][Full Text] [Related]
29. Expression and localization of matrix metalloproteinases (MT1-MMP, MMP-2) and tissue inhibitor of metalloproteinase-2 (TIMP-2) during synepitheliochorial placentation of goats (Capra hircus).
Uekita T; Yamanouchi K; Sato H; Tojo H; Seiki M; Tachi C
Placenta; 2004 Nov; 25(10):810-9. PubMed ID: 15451196
[TBL] [Abstract][Full Text] [Related]
30. [The role of disequilibrium of expression of matrix metalloproteinase-2/9 and their tissue inhibitors in pathogenesis of hyperoxia-induced acute lung injury in mice].
Zhang XF; Zhu GF; Liu S; Foda HD
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2008 Oct; 20(10):597-600. PubMed ID: 18926070
[TBL] [Abstract][Full Text] [Related]
31. E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions.
Davidson B; Berner A; Nesland JM; Risberg B; Berner HS; Tropè CG; Kristensen GB; Bryne M; Ann Florenes V
J Pathol; 2000 Dec; 192(4):460-9. PubMed ID: 11113863
[TBL] [Abstract][Full Text] [Related]
32. Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1 and TIMP-2 in the epithelium and stroma of salivary gland pleomorphic adenomas.
Zhang X; Wang Y; Yamamoto G; Tachikawa T
Histopathology; 2009 Sep; 55(3):250-60. PubMed ID: 19723139
[TBL] [Abstract][Full Text] [Related]
33. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
34. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.
Brenne K; Nymoen DA; Hetland TE; Trope' CG; Davidson B
Hum Pathol; 2012 Apr; 43(4):496-505. PubMed ID: 21855111
[TBL] [Abstract][Full Text] [Related]
35. Dynamic expression of mRNAs and proteins for matrix metalloproteinases and their tissue inhibitors in the primate corpus luteum during the menstrual cycle.
Young KA; Hennebold JD; Stouffer RL
Mol Hum Reprod; 2002 Sep; 8(9):833-40. PubMed ID: 12200461
[TBL] [Abstract][Full Text] [Related]
36. Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study.
Brummer O; Athar S; Riethdorf L; Löning T; Herbst H
Virchows Arch; 1999 Dec; 435(6):566-73. PubMed ID: 10628798
[TBL] [Abstract][Full Text] [Related]
37. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM
J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
[TBL] [Abstract][Full Text] [Related]
38. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression.
Hofmann UB; Westphal JR; Waas ET; Zendman AJ; Cornelissen IM; Ruiter DJ; van Muijen GN
Br J Cancer; 1999 Nov; 81(5):774-82. PubMed ID: 10555745
[TBL] [Abstract][Full Text] [Related]
39. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.
Manenti L; Paganoni P; Floriani I; Landoni F; Torri V; Buda A; Taraboletti G; Labianca R; Belotti D; Giavazzi R
Eur J Cancer; 2003 Sep; 39(13):1948-56. PubMed ID: 12932675
[TBL] [Abstract][Full Text] [Related]
40. Alterations in mRNA and protein levels of metalloproteinases-2, -9, and -14 and tissue inhibitor of metalloproteinase-2 responses to traumatic skeletal muscle injury.
Barnes BR; Szelenyi ER; Warren GL; Urso ML
Am J Physiol Cell Physiol; 2009 Dec; 297(6):C1501-8. PubMed ID: 19794148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
